Hoth Therapeutics (NASDAQ:HOTH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Hoth Therapeutics (NASDAQ:HOTH) from a sell rating to a hold rating in a report released on Saturday.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Tuesday, April 15th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $4.00.

Hoth Therapeutics Trading Up 12.0%

Shares of HOTH stock opened at $0.93 on Friday. The stock has a market cap of $12.28 million, a price-to-earnings ratio of -0.70 and a beta of 0.53. The stock has a 50-day moving average of $0.86 and a 200-day moving average of $1.00. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.07. Sell-side analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC raised its stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,946 shares of the company’s stock after purchasing an additional 13,038 shares during the quarter. Geode Capital Management LLC owned 1.39% of Hoth Therapeutics worth $72,000 as of its most recent filing with the Securities & Exchange Commission. 7.08% of the stock is owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.